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Background: Blood pressure (BP) in childhood is positively associated with BP in adulthood; it 
is important to understand influential factors of childhood BP. Child race, body mass index 
(BMI), and diet are well studied, but intrauterine exposures that may influence BP long term are 
not well explored.   
Objective: To determine if DHA supplementation during pregnancy leads to lower blood 
pressure in offspring at 4-5.5 years of age.  
Methods: We measured BP longitudinally at 6-mo intervals from 4 to 5.5 years of age in a 
cohort of 179 children whose mothers were randomized to either supplementation with the 
omega-3 fatty acid DHA (600 mg/d) or placebo during pregnancy.  
Results: Black race, child BMI and child salt intake were positively associated with systolic and 
diastolic BP. Maternal DHA status at delivery was associated with significantly lower BP at 4 
and 5 years of age. Black children whose mothers were assigned to placebo had higher BP across 
all ages compared to white children and black children whose mothers were supplemented with 
DHA. Similarly, maternal DHA supplementation protected against higher BP observed in 
children who were overweight or obese compared to healthy weight children at 4 and 5 years of 
age; and protected BP of those whose average sodium intake across all ages exceeded 1.9 g/day.  
Conclusion: Improving fetal DHA status through maternal DHA supplementation during 
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Chapter 1:  Introduction  
 
Fish consumption and DHA intake is much lower in the US compared to European and 
Asian countries (1),(2). Consequently, pregnant and lactating women in the US have 
significantly lower DHA levels in their blood and breastmilk (3). This is significant because 
DHA has been shown to lower blood pressure levels in both hypertensive and normotensive 
individuals. And some research has shown that breastfeeding leads to lower blood pressure in 
childhood (4).  Because human milk contains DHA, it has been suggested that the effect may be 
due to the DHA content of milk (5). One study looked at the effect of consuming a formula with 
DHA and arachidonic acid during infancy on childhood blood pressure and found that the 
addition of these fatty acids to formula resulted in lower blood pressure in childhood with an 
effect size similar to breastfeeding in infancy (5). Therefore, long chain polyunsaturated fatty 
acids (LCPUFA) exposure early in development may program a lower blood pressure in 
childhood. Assuming early LCPUFA exposure that includes DHA, does have a programming 
effect, one could suggest a similar effect of exposing the fetus to DHA during pregnancy. 
However, no research has been done to examine the impact of maternal DHA supplementation 
during pregnancy on blood pressure during childhood.  
Justification. Because on average pregnant women in the US consume less DHA than 
European and Asian women, US women might benefit from DHA supplementation during 
pregnancy. This benefit may extend to the health of the offspring even into childhood. If this 
were the case, improving maternal DHA intake could be a way to prevent chronic disease and 
improve the health of the growing population.  
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Overall, the purpose of my study was to investigate the impact of maternal DHA 
supplementation during pregnancy on childhood blood pressure between the ages of 4 and 5.5 
years compared to a vegetable oil placebo.  
Research question:  Does 600 mg of DHA supplementation during pregnancy lead to 















Chapter 2: Literature Review 
Diet and Blood Pressure 
Blood pressure is the force applied by the blood onto the arteries as blood is pumped by 
the heart (6). As blood pressure rises the heart must work harder to pump blood throughout the 
body (6). This increased workload can lead to damage of the heart and outcomes such as 
myocardial infarction (MI), stroke, heart failure, kidney failure, and aneurisms (6). High blood 
pressure or hypertension is defined as having a systolic pressure ≥ 140 mm Hg or a diastolic 
pressure ≥90 mm Hg (6). Primary hypertension is the most common form of high blood 
pressure, and multiple factors contribute to the development of primary hypertension including 
diet, lifestyle factors, age, gender, and race or ethnicity (7).  
Diet is a major contributor to high blood pressure. There are multiple components that 
contribute to high blood pressure including excessive sodium intake, low potassium intake, and 
increased alcohol consumption (8). The Dietary Approaches to Stop Hypertension (DASH) study 
developed a diet to target these areas of nutrition that contribute to hypertension (9). The DASH 
dietary pattern includes 8-10 servings of fruits and vegetables per day, 2-3 servings of low fat 
dairy, and less than 2.3 grams of sodium per day (9). The DASH diet was found to reduce 
systolic and diastolic blood pressure by 11.4 mm Hg and 5.5 mg Hg in those with hypertension 
and by 3.5 mm Hg and 2.1 mm Hg in those without hypertension (10). The American Heart 
Association recommends limiting sodium consumption to less than 2400 mg per day, limiting 
alcohol consumption to 1 drink for women and 2 drinks for men per day, and eating fish at least 
twice per week to improve heart health and help lower blood pressure (11). Making dietary 
changes such as appropriate intake of key nutrients related to blood pressure regulation can lead 
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to reductions in blood pressure. Specifically, increased intake of omega 3 fatty acids like 
docosahexaenoic acid (DHA: 22:6n-3) and eicosapentaenoic acid (EPA: 20:5n-3) has been 
shown to lead to a slight improvement in blood pressure in both normotensive and hypertensive 
individuals with the most benefit in individuals with hypertension (12). 
EPA and DHA are omega 3 fatty acids that have important roles in fetal development and 
have protective roles in cardiovascular health (13).
 
Fish is a common source of these essential 
fatty acids, but the body is capable of synthesizing EPA and DHA from a precursor known as 
alpha-linolenic acid (ALA) (14). ALA is found in flaxseeds, walnuts, canola and some other 
vegetable oils, as well as other fortified foods and plants (14). However, less than 0.2% of ALA 
consumed is converted to EPA and less than 0.05% is converted to DHA, so good dietary 
sources such as fish and fish oil supplements may be necessary, particularly during development 
(15). The amount of DHA and EPA varies by type of fish, with fattier fish having more omega 3 
fatty acids than leaner fish (16). Omega 3 fatty acid content can also vary based on whether the 
fish was farm raised or wild, and based on growing conditions like water temperature and season 
(16).  In a 3 ounce serving of salmon, there is 0.71 g EPA and 0.51 g of DHA (17). Cod liver oil 
provides the greatest amount of EPA and DHA, containing 6.2 g and 9.9 g per 3 ounce serving, 
respectively [10]. Because DHA and EPA levels vary by fish species, there is a large variability 
in DHA consumption per serving as a result.  
Within the western diet, fish is less commonly consumed. According to the 2009 census 
conducted by the US Census Bureau, the average person consumes 15.8 pounds of fish per year 
(1). The average yearly consumption amounts to roughly 4.8 ounces of fish per week. 
Consuming 4.8 ounces of salmon in a week, provides approximately 1.08 g EPA and 0.78 g of 
DHA or 2 grams of omega 3 fatty acids, however, most fish consumed in the US is in the form of 
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low DHA and EPA sources such as fish sandwiches, shrimp, etc. (2). The Food and Nutrition 
Board of the Institute of Medicine set an adequate intake level of 1.1 g/d for females and 1.6 g/d 
for males of ALA (18) but as noted above, the body is inefficient at converting ALA into DHA 
and EPA (15). From fish consumption alone, Americans are not meeting their needs for omega-3 
fatty acids, and they are not meeting the recommendation to consume 8-12 ounces of fish per 
week.  Increasing DHA and EPA intake could improve blood pressure levels in adults, and 
consequently improve disease outcomes.  
Extensive research has been done to assess the impact of DHA and EPA supplementation 
in normotensive and hypertensive adults. In 2014, Miller et al. (19) conducted a meta-analysis of 
over 70 studies that evaluated both fish oil supplementation as well as diet interventions. Miller 
et al. (19) found that fish oil supplements were more effective in lowering blood pressure than 
high fish intake diets. Specifically, supplementation of less than 2 g of EPA and DHA per day 
was effective in lowering systolic blood pressure, but not diastolic blood pressure; and 
supplementation of greater than 2 g per day led to a decrease in diastolic blood pressure (19). 
Furthermore, the impact of EPA and DHA supplementation was greater in hypertensive 
individuals compared to normotensive individuals (19). The results of this most recent meta-
analysis are comparable to the meta-analysis conducted by Campbell et al. in 2013 (20). In this 
analysis, Campbell et al. (20) did not include studies that looked at diet and only included 17 
studies in the analysis. Campbell et al. (20) also found that fish oil supplementation lowered 
systolic blood pressure, but could not recommend fish oil supplementation as a sole treatment for 
hypertension.  These findings are important because individuals with high blood pressure even 
when treated are at greater risk of mortality and morbidity than individuals with normal blood 
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pressure levels (21). Thus it is important to target preventive measures and focus on preventing 
hypertension starting at a young age (21). 
The prevalence of high blood pressure during childhood is on the rise partly due to the 
increasing rates of obesity during childhood. Weight as well as other factors like race, gender, 
sex, and disease, primarily heart and kidney disease, impact blood pressure levels during 
childhood (22). A study published in 2015, measured the prevalence of elevated blood pressure 
in children ages 2-17 using medical records of over 20,000 children (22). The study methods 
defined high blood pressure as > 90
th
 percentile for weight, age and height or >120/80 mm Hg 
(22). The study found that 36% of subjects had blood pressure above the 90
th
 percentile at ≥ 1 
visits during that year, and 3% of subjects had blood pressure above the 90
th
 percentile at ≥ 3 
visits during a single year (22). Within the population who had ≥ 3 high blood pressure 
measurements, 62% of those subjects had a BMI > 85
th
 percentile (22). As in adults, the risk for 
hypertension in childhood increases with body weight. Importantly,  a meta-analysis by Chen et 
al. (23) found that BP tracks from childhood to adulthood, confirming that having higher blood 
pressure in childhood increases one’s risk for hypertension (24) and atherosclerosis (25) in 
adulthood.  These findings highlight the need for preventive measures even in childhood. With 
growing obesity rates, hypertension in childhood is on the rise, and alternative treatment methods 
like diet and lifestyle modifications are needed to address this growing problem.  
As with adults, high sodium intake is also a contributor to hypertension in childhood. 
Correia-Costa et al. (26) studied the relationship between sodium intake, gender and obesity and 
its impact on blood pressure in a cross sectional cohort study of 298 Portuguese children between 
8-9 years of age (26). The study found that males consumed significantly more sodium than 
females (6.8 ± 2.4 g/d vs 6.1 ± 1.9 g/d, p-value 0.018), and overweight/obese children consumed 
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significantly more sodium than normal weight children (6.8 ± 2.4 g/d vs 6.1 ± 2.0 g/d, p=0.006). 
In addition, the study found that systolic blood pressure was positively associated with both 
sodium intake and BMI, and for every 1 gram increase in sodium intake they saw a 1.00 mm Hg 
increase in SBP in overweight/obese males (26). This effect was not seen in normal weight boys 
or in girls of any BMI category.  Yang et al. (27) analyzed the data from the 2003-2008 
NHANES survey consisting of 6235 subjects, and also found an association between sodium 
intake, BMI and BP in children and adolescents 8-18 years of age (27). Specifically, Yang et al. 
(27) found for every 1 gram increase in sodium intake there was a 1.0 mm Hg increase in SBP 
among all subjects and a 1.5 mm Hg increase in SBP among all overweight/obese participants. In 
this population, the average sodium intake was 3387 mg/d, with males consuming more sodium 
than females, normal weight subjects consuming more than overweight/obese subjects, and non-
Hispanic whites consuming more than non-Hispanic black subjects (27). These findings suggest 
that both BMI and sodium intake are positively associated with SBP, and children with elevated 
BMI are more susceptible to hypertension when consuming a high sodium diet.  
 Studies linking DHA supplementation to lower blood pressure in adulthood highlight the 
need to investigate the impact of DHA supplementation on hypertension in childhood especially 
for children exposed to high risk factors for hypertension like having a BMI >85
th
 percentile and 
consuming high amounts of sodium. Moreover, unlike in adults who have lower BP while taking 
omega 3 fatty acids, several studies in childhood suggest early exposures may lead to lower BP 
long after supplement action ceases (28), (29). Some studies have found a connection between 
breastfeeding and lower blood pressure in childhood. Specifically, past research has identified a 
positive impact of breastfeeding on blood pressure that was not seen in formula fed infants (4), 
(29), (30), (31). A physiological difference found in childhood linked to early feeding implies 
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early developmental programming related to some difference in feeding.  One factor that 
distinguishes human milk from old formulations of term and preterm formula is DHA content 
suggesting that improving early DHA status could have long term benefits in reducing blood 
pressure (5, 32). The purpose of this review is to investigate the effects of DHA supplementation 
during pregnancy on blood pressure in childhood. 
Breastfeeding and Childhood Blood Pressure 
Some research has found that children who were breastfed as infants have lower blood 
pressure than partially breastfed or exclusively formula fed infants. The following studies 
demonstrate the benefits of breastfeeding. Wilson et al. (29) found that children who were 
exclusively breastfed for > 15weeks had significantly lower blood pressure at 7.2 years of age 
(measured at 6.9-10 years) than children who were breastfed < 15 weeks or who were formula 
fed. Singhal et al. (30), compared donor breastmilk to preterm formula and standard formula and 
measured blood pressure at ages 7-8 and at ages 13-16. No difference in blood pressure was 
found at 7-8 years but blood pressure was significantly lower in both systolic and diastolic blood 
pressure at 13-16 years of age in the donor breastmilk group (30). In addition, Singhal et al. (30) 
found that the amount of breastmilk the infant received had a significant impact on blood 
pressure. The difference in findings between the two ages could be due to response bias, as 81 
percent of subjects participated in the 7-8 year follow up but only 26 percent participated in the 
13-16 year follow up (30). Another study by Lawlor et al. (31) found that at 5 years of age, 
children who were breastfed for more than 6 months had significantly lower blood pressure (-
1.19 mm Hg) than children who were breastfed less than 6 months or who were formula fed. 
Finally, Martin et al. (4) conducted a meta-analysis of 15 studies that looked at the impact of 
breastfeeding for more than 2 months on blood pressure levels in childhood and found an overall 
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1.4 mm Hg decrease in systolic blood pressure and 0.5 mm Hg decrease in diastolic blood 
pressure. These studies suggest that both the length of breastfeeding and the exclusivity of 
breastfeeding have an impact on blood pressure in childhood.  
One commonality among the above-mentioned studies is that none of the control formula 
groups were supplemented with DHA or arachidonic acid (ARA). Human milk is known to 
contain DHA and ARA, and the absence of DHA and ARA in the control formula could explain 
the differences in blood pressure between the two groups.  The earliest age in which a difference 
in blood pressure can be seen cannot be determined from current research. No major differences 
were apparent in the methods used for measuring blood pressure, but not all studies found 
differences in blood pressure at the same ages. These discrepancies suggest that more research 
needs to be done to pinpoint the age at which blood pressure differences could be found. 
Although, some research suggests there is an association between breastfeeding and 
blood pressure, there have been several studies published in recent years that have found no 
benefit of breastfeeding on blood pressure. For example, de Jong et al. (33) found no effect of 
breastfeeding on blood pressure at 9 years of age. The study included 341 subjects randomized to 
a control formula group (no DHA or AA), a LCPUFA formula group (0.45% AA and 0.30% 
DHA), and a breastfed group (33).  The study only required participants to breastfeed for 2 
months, a much shorter period than what is currently recommended. The result is comparable to 
children that were breastfed for a short period of time (< 6 months) in the studies conducted by 
Lawlor et al. (31) and Wilson et al. (29). Similarly, Martin et al. (34) and Kramer et al. (35) 
found no differences in blood pressure at 6.5 (n= 13,889) and 11.5 (n=13,616) years of age in the 
Promotion of Breastfeeding Intervention Trial (PROBIT). The purpose of the PROBIT study was 
to increase length and exclusivity of breastfeeding, and although the study resulted in great 
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increases in breastfeeding length and exclusivity at 3 months of age, they found no differences in 
blood pressure between the intervention and control groups.  But as mentioned before, length of 
breastfeeding seems to be inversely associated with BP, and 3 months of breastfeeding is a 
shorter period of time than in the studies that found a benefit of breastfeeding. In addition, the 
PROBIT trial was only designed to educate and encourage breastfeeding in the intervention 
group, and did not require exclusive breastfeeding for any period of time to participate in the 
study. Horta et al. (36) conducted a systematic review on the association between breastfeeding 
and blood pressure and found systolic blood pressure was lower in breastfed groups but this 
association was not present in larger studies, and there was no association between breastfeeding 
and diastolic blood pressure.   
Overall, the available research is not in agreement. Some randomized control trials have 
found a benefit of breastfeeding on blood pressure, but large observational studies have not 
shown an association when socioeconomic status is controlled for. More recent studies suggest 
differences in findings could be due to publication bias, small sample size, and confounding 
factors such as socioeconomic status that are not properly controlled for in observational studies.  
Although, there are many studies published on this topic, they vary by study type, sample size, 
age of first blood pressure measurement, and income status of the populations.  With such 
variability it is difficult to come to a conclusion on the benefits of breastfeeding on blood 






Impact of DHA supplementation on blood pressure in children 
Supplementation during Infancy: Human Milk. Although studies have shown that 
DHA supplementation lowers blood pressure in normotensive and hypertensive individuals, 
Larnkjear et al. (37) and Asserhoj et al. (38) found no benefit to maternal supplementation of 
DHA during breastfeeding on blood pressure at 2 to 7 years of life. Larnkjear et al.  (37)
 
recruited 122 Danish mothers who consumed < 0.4 g/d of omega 3 long chain polyunsaturated 
fatty acids ((n-3) LCPUFA) (37). This level is below the Danish national median for (n-3) 
LCPUFA intake, with the highest intake averaging around 0.82 g/d (37). The intervention group 
received 0.6 g EPA and 0.8 g DHA per day and the other group received olive oil capsules. 
Supplementation occurred during the first 4 months of life and the mothers were asked to 
exclusively breastfeed during that time. Because blood pressure data of children who were not 
exclusively breastfed for the entire 4 month period were included in the analysis, degree of 
breastfeeding was considered a covariate. Blood pressure was measured at 2.5 years of life (37) 
and at 7 years of life (38), and at neither time point did blood pressure differ between the two 
groups. Maternal DHA supplementation during lactation did not lead to a greater reduction in 
blood pressure at 2.5 or 7 years of age, however, all human milk provides DHA and the studies 
were done in countries where adults consume more DHA than in the US.  It is possible that milk 
of women not supplemented provided adequate DHA without supplementation. However, no 
studies have looked at the impact of maternal DHA supplementation during lactation in the US 
population. A benefit may exist in populations that do not consume enough DHA from diet 
alone. 
Although no benefit for child blood pressure was seen in this population, children of US 
woman may still benefit from supplementation as US fish intake is much lower than Danish fish 
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intake. More research needs to be done to determine if US populations would benefit from this 
intervention.  
DHA in Formula and Childhood Blood Pressure. It has been hypothesized that the 
presence of DHA in breastmilk has contributed to the lower blood pressure levels in children 
who were exclusively breastfed. Prior to 2002, formula was not supplemented with DHA (39). 
The addition of DHA to formula after 2002 may have helped to improve blood pressure levels in 
exclusively formula-fed children. To test this hypothesis, Forsyth et al. (5) conducted a study to 
compare term formula to term formula supplemented with DHA (0.15%-0.25% DHA). Forsyth 
et al. (5) found diastolic blood pressure and mean blood pressure at 5.8 years of age was lower in 
the LCPUFA formula group compared to the non-supplemented formula group. In addition, the 
diastolic blood pressure of the LCPUFA formula group was comparable to the breastfed infant 
control group.  
Prenatal DHA Supplementation and Childhood Blood Pressure. The impact of 
maternal DHA status during pregnancy on early fetal programming is not well studied. 
Vidakovic et al. (40), conducted a prospective cohort study assessing maternal second-trimester 
n-6: n-3 PUFA ratios using plasma glycerolphospholipid concentrations. Childhood blood 
pressure was then measured at 6 years of age. The study found that children of mother’s with 
high n-3 PUFA (wt%) during the second trimester, specifically related to high DHA (wt%) had 
lower systolic blood pressure at 6 years of age (40). No association was found with diastolic 
blood pressure. Since there has only been one study conducted in this area, there is a need for 
more research on this topic specifically for randomized control trials. Research in this area is 
necessary to better understand the benefits of DHA supplementation and its role on childhood 
blood pressure, as well as to determine mechanisms of DHA action. Current research shows that 
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DHA is required for fetal development and is preferentially provided to the infant during 
pregnancy. DHA first starts to accumulate in the fetus at 24 weeks gestation, but the amount of 
DHA that is transferred varies greatly from mother to mother depending on the mother’s own 
DHA intake (3).
 
The variability in DHA transfer makes it difficult to design a strong randomized 
controlled trial and could impact the findings of the study (3).  
Summary 
My review of the literature suggests that DHA intake in infancy does have some impact 
on blood pressure in childhood. The research on the impact of breastfeeding on blood pressure is 
extensive, but inconclusive. Some studies suggest that children that were breastfed have lower 
blood pressure during childhood compared to children who were partially breastfed or 
exclusively formula fed. However, recent studies have not found an association between 
breastfeeding and blood pressure and argue that previous study findings were due to small 
sample size and confounding factors such as socioeconomic status.  The studies in this review 
looked at a wide range of ages ranging from 2 to 17 years of age, and lower blood pressure was 
evident at these ages in some studies but not in all. Only one study compared infant formula 
supplemented with DHA, formula without DHA, and breastfeeding, and infants receiving DHA 
formula had lower blood pressure compared to infants not receiving DHA formula. However, 
more studies need to be done to confirm this finding.  
Maternal DHA supplementation during pregnancy could also increase DHA supply at a 
critical early period of development; however, the impact of increasing fetal supply on childhood 
blood pressure is less widely studied. A prospective cohort study did associate higher DHA 
plasma levels during pregnancy with lower systolic blood pressure at 6 years of age (40), but no 
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research has looked at the impact of maternal DHA supplementation during pregnancy and blood 
pressure in childhood.   
The literature suggests that DHA has an important role in lowering blood pressure, and 
that excessive sodium intake and elevated BMI both play a role in raising blood pressure.  What 
we do not know is whether supplementing DHA during pregnancy will lead to lower blood 
pressure in childhood and if DHA supplementation might lower the offspring’s risk of high 
blood pressure when exposed to risk factors such as excessive sodium intake or elevated BMI. 















Chapter 3: Methods  
Subjects 
The purpose of this study is to determine whether DHA supplementation during 
pregnancy leads to lower blood pressure in children between 4 and 5.5 years of age. The KU 
DHA Outcomes Study (KUDOS) was a phase III placebo controlled randomized clinical trial 
that looked at the effects of DHA supplementation during pregnancy on gestational duration, 
birth size, length, and maternal and newborn DHA status. Mothers were recruited from the 
Kansas City Metropolitan Area between January 2006 and November 2009. To participate in the 
study, mothers had to speak English, be between 8 and 20 weeks gestation, 16 - 35.99 years of 
age, and planning to deliver in a hospital in the Kansas City area. Exclusion criteria were as 
follows: pre-existing DM, hypertension, preexisting health condition such as HIV/AIDs, 
hepatitis, lupus, cancer, and alcohol or drug dependency that could impact growth and 
development, and morbid obesity (BMI>40).  The study followed an intent to treat protocol and 
included 3 females with a BMI >40.  
The NIH also funded developmental follow up of the children to age 6. A total of 179 
children (of 350 mothers enrolled) continued to participate in follow up visits after age 4.  Blood 
pressure measurements were taken every 6 months starting at 4 years of age and continued 







Study subjects were recruited from the Kansas City metropolitan area between January 
2006 and November 2009. Data continues to be collected as the remaining participants reach 6 
years of age.  
Ethics 
The KUDOS study was approved by the University of Kansas Medical Center Human 
Subjects Committee # 10186 and 11406. Both the research protocol and informed consent 
process were in compliance with the Declaration of Helsinki, and were approved by the 
Institutional Review Boards/Human Subjects Committee at the University of Kansas Medical 
Center, the University of Missouri-Kansas City; and St Luke’s Hospital. The proposed project is 
covered by the existing protocol.  
DHA Supplementation and Blood DHA Analysis 
Pregnant participants were randomized into one of two groups. To account for potential 
bias of age at enrollment, randomization was stratified by age (16-25.99 or 26-35.99). The 
experimental group received 600 mg/d DHA in the form of 3 capsules each containing 200mg of 
DHA. The placebo group also received 3 capsules per day containing equal parts soybean oil and 
corn oil. Orange flavoring was used to conceal the identity of the placebo and DHA capsules. 
The participants were instructed to take 3 capsules per day until delivery. Each month the 
subjects were mailed a month’s worth of capsules and were supplied a self-addressed stamped 
envelope to return the previous bottle. Upon receiving the sealed envelope the pharmacy staff 
counted the remaining capsules, and this count was used to assess total DHA intake and 
compliance at the end of the study.   
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Prior to randomization, a blood sample was drawn from the mother. Fatty acids were 
analyzed as described previously (41).  Briefly, red blood cell (RBC) lipids were extracted by a 
modified procedure of Folch et al. (42) and RBC phospholipids were separated using thin-layer 
chromatography (43). RBC phospholipids were then trans-methylated using boron trifluoride-
methanol resulting in fatty acid methyl esters (FAMES) (44). Next the FAMES were separated 
using a Varian 3900 gas chromatograph with a 100 meter capillary column (SP-2560; Sigma 
Aldrich). Peak integration and analysis was performed using a Star 6.41 Chromatography 
Workstation (41).  Qualitative standards (PUFA 1 and PUFA 2; Sigma Aldrich) and a weighed 
standard mixture (Supelco 37 Component FAME mix) was used to identify individual peaks and 
to calculate a final percentage weight of total fatty acids (41).  Individual RBC-phospholipid 
fatty acid levels were reported as a percentage of total fatty acid by weight (wt %).  Following 
delivery, a second blood sample was drawn and analyzed for fatty acids.  Change in DHA wt% 
was used examine the effect of the intervention (placebo vs DHA).  
Blood Pressure Assessment and Reporting 
Beginning at 4 years of life, blood pressure measurements were taken every 6 months in 
the offspring. Blood pressure was measured using a GE Carescape V100. At the end of a 60 
minute cognitive assessment, the child was wheeled to the room where blood pressure was 
measured. The child remained seated while their blood pressure was measured in triplicate. Child 
and toddler size cuffs were used to conduct blood pressure measurements unless a larger size 
was necessary. The cuff was applied by wrapping it around the upper arm, aligning the arrow 
marked artery with the patient’s brachial artery (45). Appropriate cuff size was chosen by 
making sure the Index line on the cuff fell between the range marks on the cuff as the cuff was 
wrapped around the patient’s arm (45). If the index line did not fall between the range marks a 
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larger or smaller cuff was chosen (45).  Measurements were taken 3 times by research staff 
trained in this procedure. Average systolic and diastolic measurements were calculated using the 
last two measures, coefficient of variance (CV) was then calculated for each average. If the CV 
was >0.095, the two measures closest in number were selected to calculate the average, rather 
than the last two. The method was applied to 9.2% of SBP measurements and 19.4% of DBP 
measurements. This method was applied across all age groups. Reasons for missing BP data 
include irritated or restless children, or mechanical failure. The measurements with only one data 
point were excluded from analysis (n= 23).   
Blood pressure and BMI percentiles were calculated using the EZ BMI/BP calculator 
software version 2013. The software uses the child’s age, gender, and height to determine the BP 
percentile, and age and gender are used for BMI percentile calculations.  
Dietary Intake 
Food, formula, and human milk intake were obtained by a registered dietitian using a 
standardized multipass-24-hour recall method at each visit throughout the study (46). In infancy, 
recalls were obtained at 6 weeks, 4, 6, 9 and 12 months.  From age 1 to 5.5 years, recalls were 
obtained at 6 month intervals. A dietary recall kit that included bean bags, bowls, cups, 
measuring cups and spoons, as well as food pictures was used to assist the parents in completing 
the dietary recall. Recalls were entered into Nutrition Data System for Research (NDSR) 
(versions 2008-2014, University of Minnesota), and assessed for accuracy by a second registered 
dietitian. A dietary recall was deemed unreliable when the parent or child was unable to recall 
multiple meals in the 24 hour period. In addition, dietary recalls were assessed for quality 
assurance when the calorie intake was above 2100 calories or below 912 calories. If it was found 
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that the calorie intake was inaccurate due to the parent or child being unable to recall one or 
more meals the recall was considered unreliable. These recalls were excluded from analysis. 
Recalls were included in analysis when a child consumed less than usual due to illness.  
Dietary sodium intake from 12 months to 5 years of age was averaged across ages. For 
analysis, participants were grouped by sodium intake above and below 1.9g/d based on US 
Dietary Reference Intakes (DRI) for children 4-8 years of age (DRI for children 4 - 8 years of 
age is < 1.9g Na/d) (47).  
Database  
The database includes average blood pressure at each age, maternal characteristics 
including age, BMI, DHA supplement intake, DHA status at enrollment and delivery, smoking 
status, race and weight gain in pregnancy; and data on the child including birthweight, diet from 
birth to 5.5 years of age, BMI percentile at 2-5 years of age, body composition at age 5, and sex. 
Treatment group was added by one of the study primary investigators in possession of the 
randomization data as the study is still masked to staff.  
Statistical Analysis 
First we looked at the effect of supplementation on blood pressure using an intent to treat 
analysis and a one tailed t-test. Then we examined a number of potential covariates that had been 
associated with blood pressure including maternal characteristics [race, BMI, gestational weight 
gain, DHA status (RBC phospholipid DHA wt %), smoking status] and child characteristics 
(BMI percentile, percent body fat at 5 years, sex, average sodium intake from 12 months-5.5 
years, and length of breastfeeding) by calculating the mean and standard error of the mean for 
each variable. In addition, we performed one tail t-tests on several variables including race, 
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sodium intake, maternal smoking status, breastfeeding days, and child BMI percentile at 4 and 5 
years. We also looked at body fat percentage at 5 years.  From this we identified three variables 
that seemed to have the greatest impact on blood pressure: maternal race, child BMI percentile, 
and child sodium intake. Next we ran a correlation matrix and found relationships among those 
three variables. The statistical software SAS version 9.4 was used to run a PROC MIXED 
repeated measures ANOVA. PROC MIXED repeated measures were performed to allow for 
missing data since all participants were included that participated in blood pressure measurement 
at a minimum of one age time point. Several models were created: 1) model BP=maternal race, 
treatment and treatment by year; 2) model BP= Na intake >1.9g/d, treatment, and treatment by 
year 3) model BP = 5 year BMI percentile, treatment, and treatment by year 4) model BP= 
treatment, maternal race, gestation smoke, and treatment by year. Each model was run for SBP, 
DBP as well as SBP percentiles and DBP percentiles. Finally PROC frequency measures were 
performed to determine if there were any differences in the frequency of high sodium intake by 





















Chapter 4: Results  
 
 
Our hypothesis was that DHA supplementation would lead to lower BP in childhood. 
Participant characteristics were similar between the placebo and DHA group. Maternal and child 
characteristics are given in Table 1.  The total number of BP measurements at each age group is 
depicted in Figure 1.  
Maternal LCPUFA status at enrollment and postpartum 
Maternal LCPUFA (wt %) can be found in Table 2. DHA supplementation resulted in an 
increase in total n-3 LCPUFA (wt %) (p-value < 0.0001), specifically an increase in DHA (wt %) 
(p-value < 0.0001), as well as a decrease in both total n-6 LCPUFA (wt %) (p- value <0.0001) 
and total ratio of n-6: n-3 LCPUFA (p-value < 0.0001).  
DHA Supplementation and Child Blood Pressure 
The DHA group had lower average SBP at 4, 4.5 and 5 years, and also had lower average 
DBP at all ages (Table 3). The intervention lead to an average drop in SBP of 1.383 mm Hg (P-
value = 0.031) and an average drop in DBP of 1.72 mm Hg (P-value = 0.0075) before controlling 
for other variables. Six percent of children in the placebo group and 3 % of children in the DHA 
group had pre-hypertensive BP (>90
th
 percentile) (Table 4). In addition, 5 % of children in the 
placebo group and  2 % of children in the DHA group had hypertensive BP (>95
th
 percentile) 
(Table 4).  
BMI percentile at 5 years and Blood Pressure 
We saw a significant effect of 5 year BMI percentile on DBP percent and DBP (P-values = 
0.0379 and 0.0022 respectively). The same effect was observed for SBP percent and SBP as  
22 
 
Table 1 Characteristics of mothers and their children participating in the KUDOS 
study (n=179) 
  Value 
Maternal Characteristics Placebo group DHA group 
Age at enrollment (y) 26 ± 4.8 26.4 ± 4.8 
Gestational age at enrollment (wk) 15.0 ± 3.5 14.4 ± 3.5 
Maternal BMI 25.3 ± 5.1 25.9 ± 5.0 
Pregnancy weight gain  (lbs) 35 ± 15.5 39 ± 15.1 
Black, (n) 28 25 
Not-black, (n)  58 68 
Mother Hispanic, (n)  6 4 
Ever smoked (%) 44 49 
Preeclampsia, (n)  2 3 
Total capsules taken (#) 427.5 ± 122.1 426.7 ± 112.0 
Capsules (#/wk) 17.1 ± 4.0 17.5 ± 3.9 
Breastfeeding (d) 190 ± 221.3 205.9 ± 245.5 
Formula (d) 254.7 ± 161.9 279.7 ± 138.5 
Additional DHA intake (n)  17 13 
Additional DHA (mg) 221.7 ± 91.2   227.7 ± 80.6 
Childhood Characteristics   
Males/Females (n)  48/38 41/52 
2yr BMI percentile 61.6 ± 29.8 65.6 ± 24.0 
3yr BMI percentile 60.9 ± 26.2 66.4 ± 26.6 
4yr BMI percentile 62 ± 27.2 70.1 ±26.1 
5yr BMI percentile 64.2 ± 26.2 69.6 ±25.0 
5yr Fat Mass (%) 25.0 ± 6.5 24.8 ± 5.2 
Sodium intake (mg/d)* 1977 ± 514.3 1901 ± 544.6 
Birth weight (g) 3266 ± 522.3 3441 ± 485.1 
* Sodium intake was calculated as the average across all ages studied (12mo -5years). 
















Table 2 Maternal RBC LCPUFA* concentrations at enrollment and 
postpartum in the Placebo and DHA groups of the KUDOS study (n=179) 
RBC LCPUFA 
concentrations 
Placebo group DHA group 
 Enroll PP Enroll PP 
  FAs, wt % FAs, wt % 
Total n-3 LCPUFAs 6.4 ± 1.4 6.3 ± 1.3 6.3 ± 1.3  9.0 ± 2.1 
20:3n-3 Eicosatrienoic acid 0.1 ± 0.3 0.1 ± 0.2 0.1 ± 0.2 0.1 ± 0.1 
20:5n-3Eicosapentaenoic acid 0.3 ± 0.2 0.2 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 
22:5n-3 Docasapentaenoic acid 1.6 ± 0.3 1.4 ± 0.3 1.5 ± 0.3 1.0 ± 0.3 
22:6n-3 Docosahexaenoic acid 4.3 ± 1.2 4.6 ± 1.0 4.4 ± 1.1 7.6 ± 2.0 
Total n-6 LCPUFAs 20.9 ± 2.7 19.0 ± 2.5 20.9 ± 2.5 17.3 ± 2.8 
20:3n-6 DGLA 1.8 ± 0.5 1.8 ± 0.5 1.7 ± 0.6 1.7 ± 0.5 
20:4n-6 Arachidonic acid 14.9 ± 2.3 13.2 ± 1.8 14.9 ± 1.9 12.4 ± 2.0 
22:2n-6 Docosadienoic acid 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.2 0.1 ± 0.1 
22:4n-6 Docosatetraenoic acid 3.4 ± 0.7 3.1 ± 0.8 3.5 ± 0.8 2.5 ± 0.7 
22:5n-6 Docosapentaenoate  0.8 ± 0.3 0.9 ± 0.3 0.8 ± 0.2 0.6 ± 0.3 
Total n-6:n-3 LCPUFA ratio 3.3 ± 0.8 3.1 ± 0.6 3.4 ± 0.7 2.1 ± 0.7 
*LCPUFA: Long chain polyunsaturated fatty acids 









Table 3 Average childhood blood pressure in control and DHA groups 










4y 99.8 ± 11.6 97.2 ±7.7 0.058 
4.5y 100.7 ± 9.7 99.1 ± 7.8 0.136 
5y 99.2 ± 7.5 97.0 ± 6.4 0.026 
5.5y 102.0 ± 10.9 102.7 ± 10 0.328 
DBP 
4y 61.2 ± 10.9 57.9 ± 6.6 0.016 
4.5y 62.6 ± 10.4 60.4 ± 5.5 0.053 
5y 58.4 ± 6.3 57.6 ± 5.2 0.196 
5.5y 62.5 ± 11.1 61.8 ± 10.5 0.339 
* Values represent mean ± SD    
SBP: Systolic Blood Pressure    










Table 4 Pre-hypertensive and Hypertensive blood pressure percentiles.  
  Placebo  DHA 
Blood Pressure Percentile >90% >95% >90% >95% 
4y SBP n (%) 5(7) 4(6) 4(5) 2(2) 
4.5y SBP n (%) 5(6) 8(10) 4(5) 2(2) 
5y SBP n (%) 3(4) 5(7) 2(2) 0(0) 
5.5y SBP n (%) 5(7) 7(9) 6(7) 7(8) 
4y DBP n (%) 7(10) 6(9) 2(2) 2(2) 
4.5y DBP n (%) 7(9) 6(8) 3(4) 2(2) 
5y DBP n (%) 4(5) 2(3) 1(1) 0(0) 
5.5y DBP n (%) 7(9) 4(5) 3(4) 4(5) 
*BP above the 90th percentile is considered pre-hypertension, and above 









well (p-values = 0.0042 and 0.0003). Average BMI percentile for black and not-black subjects is 
reported in Table 5.  Children in the placebo group with a BMI percentile > 85
th
 percentile at 5 
years had a significantly greater SBP at 4, 5 and 5.5 years and a significantly greater DBP at all 
ages when analyzed with a 1-tailed t-test. This relationship is depicted in Figure 2. We also 
looked at 4 year BMI percentile but a significant difference in blood pressure was not observed.  
Maternal Race and Blood Pressure 
We found a significant effect of race on DBP percentile (p-value = 0.0318) and a trend on 
DBP (p-value = 0.1108) after running a PROC Mixed repeated measures ANOVA. There was a 
similar trend with Race and SBP percentiles (p-value = 0.1573) and SBP (p-value = 0.0543). 
Figure 3 shows the relationships between race and blood pressure. In general, black children in 
the placebo group had significantly higher DBP than placebo white, DHA white, and DHA black 
children at ages 4y and 4.5y. SBP was higher in black children in the placebo group as well but 
this was not significant.  
Average Sodium intake and Blood Pressure 
We found no significant effect of average sodium intake on blood pressure. Consuming 
an average sodium intake above 1.9 g/day had no effect on DBP or DBP percentile (p-value = 
0.3275 and 0.3356 respectively) or on SBP or SBP percentile (p-value =0.1140 and 0.4098 
respectively). More black children in the placebo group consumed >1.9 g Na/day (64.3%) than 





Table 5: Child Characteristics by Race from KUDOS study (n=179) 
  Placebo DHA  
Child Characteristics Black Not-black Black Not-black 
Sample size, (n) 28 58 25 68 
Sodium intake (mg/d) 2128 ± 481.7 1904.5 ± 517.7 2008.8 ± 862 1861.5 ± 367.7 
Sodium >1.9g/d (%) 64.3 44.8 48 45.6 
2yr BMI percentile 48.4 ± 23.4  68.4 ± 30.9 60.2 ± 24.5 67.1 ± 24 
3yr BMI percentile 61.3 ± 22.5 60.6 ± 28.1 65.8 ± 29.6 66.6 ± 25.7 
4yr BMI percentile 66.8 ± 24.6 59.7 ± 28.3 66.2 ± 28.8 71.6 ± 25.1 
5yr BMI percentile 73.6 ± 21 59.5 ± 27.4 70.7 ± 26.3 69.1 ± 24.8 
5yr Body Fat (%) 23.9 ± 7.2 25.5 ± 6.2 23.7 ± 6.9 25.1 ± 4.6 
Breastfeeding (d) 100 ± 197.4 235 ± 220.4 81.1 ± 160.3 251.8 ± 256.2 
Males/Females (n) 16/12 32/26 14/11 27/41 
Smoking during pregnancy, (%) 46 31 36 26 
Smoking during pregnancy, (d) 77.8 ± 118.3 35.6 ± 83.4 80.4 ± 122.9 35.1 ± 83.8 
Birth weight (g) 3253.7 ± 426.8 3272.4 ± 566  3182.6 ± 533.3 3535.7 ± 432.6 
Values represent means ± SD     









Black children consumed >1.9 g Na/d than not-black children in the placebo group 
(64.3% vs 44.83%, p-value = 0.09087), but there was no difference in the proportion of children 
whose sodium intake was above 1.9 g/d between black and not-black children in the DHA group 
(45.59% >1.9 g Na/d not-black vs 48% >1.9 g Na/d black, p-value 0.8362). 
Figure 4 depicts the differences in average blood pressure between the two treatment 
groups based on average sodium intake above 1.9 g/d. Blood pressure of children who consumed 
on average more than 1.9 g/d sodium had significantly higher blood pressure than the placebo 
group that did not consume greater than 1.9 g sodium/ day and both DHA groups, whether they 
consume >1.9 g/d or not for SBP at ages 4, 4.5 and 5 years, and for DBP at 4.5 and 5.5y.  
Differences in Child Characteristics by Race 
We noted some differences in characteristics between treatment groups of the black 
children. First, 64% of black children in the placebo group consumed >1.9 g Na/day (mean = 
2128 g/d) whereas in the DHA group, only 48% of black children consumed >1.9 g/d (mean = 
2008.8 g/d). No difference in average sodium intake was seen in not-black children between the 
DHA and Placebo groups. In black children, BMI percentiles were similar in both placebo and 
DHA groups at 4 and 5 years, but in white children BMI percentiles were much higher in the 
DHA group at 4 and 5 years. In addition, not-black mothers breastfed twice as long as black 







Maternal Smoking and Blood Pressure 
Smoking during pregnancy did not have significant impact on blood pressure in either 
group. Relationships between maternal smoking status during pregnancy and blood pressure can 
be seen in Figure 5.  
Breastfeeding and Blood Pressure 
We looked at the effect of breastfeeding days on blood pressure, and assessed differences 
in blood pressure based on breastfeeding for > 60 days and for >6 months. We found a negative 
correlation between length of breastfeeding and blood pressure at several time points, but this 
was not significant.  
Body fat % at 5 years and Blood Pressure 
The mean body fat percentage at 5 years of age was 24.8 ± 5.2 for the DHA group and 
25.0 ± 6.5 for the placebo group. Using this information we looked at blood pressure of children 
with greater than and less than 25 percent body fat in each treatment group. At 5 years of age the 
children with body fat >25% in the placebo group had slightly higher blood pressure than the 












Several other relationships between smoking during pregnancy, breastfeeding, and Na 
intake and BMI were found. There was a negative correlation between total breastfeeding days 
and smoking during pregnancy (r=-0.311, p <0.00001). We also found a positive correlation 
between days smoked during pregnancy and average sodium intake (r = 0.224, p-value = 0.001).  
In addition, we found a negative correlation between total breastfeeding days and average 
sodium intake (r = -.232, p-value = 0.0009). A positive though not significant correlation was 
also found between BMI and sodium intake at 4 (r = 0.13, p-value = 0.083) and 5 years of age (r 














Chapter 5: Discussion  
DHA Supplementation and Blood Pressure 
In this study, we found that DHA supplementation during pregnancy led to lower SBP at 
4, 4.5 and 5 years of age and lower DBP at all ages. This confirms our hypothesis that DHA 
supplementation would lead to lower blood pressure in childhood. Despite this lowering effect, 
we did not see an effect on SBP at 5.5 years of age.  Overall, there was a lot of variability in the 
blood pressure measurements, and our analysis methods helped to reduce this variability, but not 
completely.  
In our analysis we also looked at a number of factors that are known to be associated with 
BP including BMI, Na intake, race, breastfeeding, and maternal smoking status. What we found 
was a protective effect of DHA against higher SBP and DBP in children carrying these risk 
factors specifically BMI >85
th
 percentile, black race and Na intake >1.9g/d (Figures 2, 3 and 4).  
Maternal PUFA status and Blood Pressure 
DHA supplementation resulted in a significant increase in maternal DHA postpartum, as 
well as a decrease in total PUFA n-6: n-3 ratio. Our findings that DHA supplementation leads to 
improved LCPUFA profiles in the mother, and lower SBP in the child confirms the observational 
study findings of Vidakovic et al. (40).  This is only the second study to look at the impact of 
maternal LCPUFA status during pregnancy and its impact on blood pressure in childhood, and it 
is the first randomized control trial to assess the impact of DHA supplementation during 
pregnancy on childhood blood pressure. Our findings suggest that supplementing with DHA 
during pregnancy may cause an intrauterine programming effect that leads to lower BP in 
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childhood. This finding is important as hypertension and obesity in childhood is increasingly 
more common, and certain populations are at greater risk for these health issues than others. 
5 year BMI percentile and Blood Pressure 
Research has shown that being overweight or obese increases one’s risk for hypertension. 
In our study we found that the BP of children in the placebo group whose BMI was above the 
85th percentile (the marker for overweight and obesity in childhood) was significantly greater 
than children with BMI less than the 85
th
 percentile in both groups and the children in the DHA 
group with a BMI percentile greater than the 85
th
. This finding was significant at 4.5, 5, and 5.5 
years in both SBP and DBP. Overall, BMI percentile at 5 years was the most powerful variable 
that significantly predicted both SBP and DBP.  
Race and Blood Pressure 
Individuals of African descent are known to have a greater risk for hypertension in life. In 
our study we found that black children in the placebo group had the highest DBP among all the 
groups at all ages, and the highest SBP at 4.5, 5 and 5.5 years of age. However, we found that 
black children whose mothers received DHA had blood pressure that more closely resembled 
that of not-black children from the placebo group and from the DHA group. This difference with 
supplementation is suggestive of a possible protective effect of DHA on blood pressure, and it 
highlights a method of prevention that clinicians could use to lower the risk of hypertension in 





Sodium intake and Blood pressure 
Sodium intake was higher among black children than among not-black children (mean: 
2.1g/d vs 1.9g/d respectively). Like with race, the placebo group that consumed >1.9g Na/d had 
higher DBP and SBP at 4, 4.5, and 5 years of age and the difference was significant at 4, 4.5, and 
5 years for SBP and it was significant at 4.5 and 5.5 years for DBP compared to the BP of 
children in the DHA group who consumed > 1.9 g/d. The blood pressure of children in the DHA 
group consuming more than 1.9 g Na/day more closely matched the blood pressure of children 
consuming less than 1.9g/d on average.   
Maternal Smoking and Blood Pressure 
Several studies have found a positive association between maternal smoking during 
pregnancy and childhood blood pressure (48), (31), (49), (50). However, Bergel et al. (51) found 
no association and our results are in agreement with Bergel et al.  More research is needed in this 
area, and although we did not find an association between DHA supplementation and smoking 
this remains an interesting area of study.  
Breastfeeding and Blood pressure 
We found a negative but not significant correlation between breastfeeding days and BP. 
Our findings confirm the most recent studies as we did not find any significant differences in 
blood pressure between children that were breastfed greater than 6 months and children breastfed 
less than 6 months. One reason for this could be due to socioeconomic differences as well as 
differences in length of breastfeeding between black and not-black participants (Mean: 91 days 
vs 243 days respectively) since some research has shown that length of breastfeeding plays a role 
in blood pressure outcomes.  
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Implications of Findings 
Our findings that maternal DHA supplementation led to lower blood pressure in 
childhood emphasizes the importance of DHA supplementation as a preventive measure for 
future disease. Our results suggest that n-3 LCPUFA supplementation in US pregnant women 
has a greater impact on childhood health than previously known. With the rise in childhood 
obesity rates, childhood blood pressure is also on the rise. Because DHA supplementation during 
pregnancy led to lower blood pressure in childhood especially in children exposed to risk factors 
for hypertension, this highlights the need for greater intake of DHA during pregnancy to protect 
against the risk for hypertension in childhood. Achieving optimal health and nutrition status 
during pregnancy is one approach to lowering risk for future disease.  
Future Studies 
More randomized control trials in this area are necessary to confirm our findings. 
Furthermore, studies are needed to determine what minimum dose of DHA is necessary to 
achieve this effect on BP in childhood. The dose used in this study (600 mg/d) is much higher 
than current doses found in prenatal vitamins (250 mg DHA is most common in prenatal 
supplements). The results of the study suggest that DHA may protect against risk factors for high 








 One major limitation of the study is the method used to measure blood pressure. Because 
blood pressure was not a primary outcome, the method used was not as precise as methods used 
in previously conducted studies. Children were not asked to remain still for any period of time 
although they had been sitting for another test prior to blood pressure measurement and were 
wheeled to the assessment room. Furthermore, the measurements were taken successively with 
no rest time in between.  Because blood pressure was not a primary outcome, the measurement 
method likely contributed to the variability in measurement data.  
Another limitation of the study was that women who were already taking <300mg/d of 
DHA prior to the KUDOS study were not excluded from the study. In fact 17% of women in the 
placebo group and 10% of the women in the experimental group were taking DHA that was not 
given as part of the study.  This may explain why we found higher correlations between some 
variables and the difference in DHA status between enrollment and delivery of the child when 
using an intent-to-treat analysis. 
Conclusions 
Overall, we found that BMI > 85
th
 percentile, Na intake >1.9g/d and black race were 
significant risk factors for high BP, but from these relationships we cannot say what is the cause 
of higher blood pressure in the high risk groups. However, these relationships suggest that DHA 
protects against higher BP in the high risk groups. In conclusion, DHA supplementation during 
pregnancy leads to lower blood pressure in the offspring, and protects against well known risk 
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